In Re "Agent Orange" Product Liability Litigation Mdl No. 381

818 F.2d 187, 1987 U.S. App. LEXIS 5507
Court of Appeals for the Second Circuit·Decided April 21, 1987·No. 1085, 1095 and 1104, Dockets 85-6163, 85-6269 and 85-6337·Published·Cited by 130 cases

Opinion

WINTER, Circuit Judge:

This opinion addresses the disposition of 287 appeals in cases brought by plaintiffs who chose to opt out of the Agent Orange class action. These cases remained in the *189 Eastern District of New York after the class settlement as a result of the multidistrict referral. Chief Judge Weinstein granted summary judgment against each of the optout plaintiffs, most of whom now appeal. 1 To avoid repetition, this opinion assumes familiarity with the discussion of the fairness of the settlement in the first of this series of opinions, 818 F.2d 145, and with Chief Judge Weinstein’s opinions reported at: 597 F.Supp. 740, 775-99, 819-50 (E.D.N.Y.1984) (“Settlement Opinion"); 611 F.Supp. 1223 (E.D.N.Y.1985) (“Opt-Out Opinion”); and 611 F.Supp. 1267 (E.D.N.Y.1985) ("Lilley Opinion”).

After they had settled with the class, the defendant chemical companies moved for summary judgment against the opt-out plaintiffs. Chief Judge Weinstein granted the motion on the alternative dispositive grounds that no opt-out plaintiff could prove that a particular ailment was caused by Agent Orange, see Opt-Out Opinion, 611 F.Supp. at 1260-63; Lilley Opinion, 611 F.Supp. at 1284-85, that no plaintiff could prove which defendant had manufactured the Agent Orange that allegedly caused his or her injury, see Opt-Out Opinion, 611 F.Supp. at 1263; Lilley Opinion, 611 F.Supp. at 1285, and that all the claims were barred by the military contractor defense. See Opt-Out Opinion, 611 F.Supp. at 1263-64; Lilley Opinion, 611 F.Supp. at 1285.

The district court’s determination that individual causation could not be proven was based largely on its conclusion that the expert opinions submitted by the opt-out plaintiffs were inadmissible. Chief Judge Weinstein held that the opinions lacked a reliable basis and were therefore inadmissible under Fed.R.Evid. 703. 2 See Opt-Out Opinion, 611 F.Supp. at 1243-55; Lilley Opinion, 611 F.Supp. at 1280-83. He also found that the opinions were so unreliable that the danger of prejudice substantially outweighed their probative value under Fed.R.Evid. 403. 3 See Opt-Out Opinion, 611 F.Supp. at 1255-56; Lilley Opinion, 611 F.Supp. at 1283.

The district court’s determination that no plaintiff could prove which defendant caused his or her particular illness was based on the undisputed facts that the amount of dioxin in Agent Orange varied according to its manufacturer and that the government often mixed the Agent Orange of different manufacturers and always stored the herbicide in unlabeled barrels. See Opt-Out Opinion, 611 F.Supp. at 1263 (citing Settlement Opinion, 597 F.Supp. at 816-44). The court also rejected sub silentio various theories of enterprise and alternative liability that it had discussed in evaluating the settlement. See Settlement Opinion, 597 F.Supp. at 820-28. We do not address either of these grounds for the grant of summary judgment because we affirm on the military contractor defense. 4

The district court granted summary judgment on military contractor grounds because it found no genuine factual dispute as to whether the government possessed as much information as the chemical companies about possible hazards of Agent Orange at pertinent times. See Opt-Out Opinion, 611 F.Supp. at 1263. This information concerned an association between *190 dioxin exposure and cases of chloracne and liver damage. We agree with the district court that the information possessed by the government at pertinent times was as great as, or greater than, that possessed by the chemical companies. We add a further reason for affirming the grant of summary judgment based on the military contractor defense. Even today, the weight of present scientific evidence does not establish that Agent Orange injured personnel in Vietnam, even with regard to chloracne and liver damage. The chemical companies therefore could not have breached a duty to inform the government of hazards years earlier.

Our consideration of the military contractor defense has been greatly impaired by the inexplicable and unjustifiable failure of the opt-outs’ counsel to brief the issue even though it was a dispositive ground for the grant of summary judgment. 5 On appeal, their brief offers only the conclusory statement that “[t]he district court clearly committed error in holding that the government contract defense presented no genuine issues of material fact.” We are then referred to 569 pages of deposition excerpts and documents, which are said to “raise clear questions of material fact.” 6 No explanation is given of the relevance of these materials, however, and we are left in ignorance of appellants’ view of the legal contours of the defense. Appellees, having no discussion to which they might respond, also do not address the issue.

We believe that federal law shields a contractor from liability for injuries caused by products ordered by the government for a distinctly military use, so long as it informs the government of known hazards or the information possessed by the government regarding those hazards is equal to that possessed by the contractor. The military contractor defense has been the subject of several recent judicial decisions, see Boyle v. United Technologies Corp., 792 F.2d 413, 414-15 (4th Cir.1986), cert. granted, — U.S. -, 107 S.Ct. 872, 93 L.Ed.2d 827 (1987); Tozer v. LTV Corp., 792 F.2d 403 (4th Cir.1986), petition for cert. filed, 55 U.S.L.W. 3337 (U.S. Oct. 23, 1986) (No. 86-674); Shaw v. Grumman Aerospace Corp., 778 F.2d 736 (11th Cir.1985), pet ition for cert. filed, 54 U.S.L.W. 3632 (U.S. Mar. 17, 1986) (No. 85-1529); Bynum v. FMC Corp., 770 F.2d 556 (5th Cir.1985); Tillett v. J.I. Case Co., 756 F.2d 591, 596-600 (7th Cir.1985); Koutsoubos v. Boeing Vertol, 755 F.2d 352 (3d Cir.), cert.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re "Agent Orange" Product Liability Litigation Mdl No. 381, 818 F.2d 187, 1987 U.S. App. LEXIS 5507 (2d Cir. 1987).

818 F.2d 187 (In Re "Agent Orange" Product Liability Litigation Mdl No. 381) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Joe McGinty v. Grand Casinos of Mississippi, Inc.- Biloxi
245 So. 3d 444 (Mississippi Supreme Court, 2018)
Acosta v. Shell Western Exploration & Production, Inc.
2013 NMCA 009 (New Mexico Court of Appeals, 2012)
Acosta v. Shell W. Expl. & Prod., Inc.
2013 NMCA 9 (New Mexico Court of Appeals, 2012)
Anderson v. AKZO NOBEL COATINGS, INC.
260 P.3d 857 (Washington Supreme Court, 2011)
Wagoner v. Exxon Mobil Corp.
813 F. Supp. 2d 771 (E.D. Louisiana, 2011)
Noveck v. PV Holdings Corp.
742 F. Supp. 2d 284 (E.D. New York, 2010)
Pacheco v. New York Presbyterian Hospital
593 F. Supp. 2d 599 (S.D. New York, 2009)
Loeffel Steel Products, Inc. v. Delta Brands, Inc.
387 F. Supp. 2d 794 (N.D. Illinois, 2005)
Isaacson v. Dow Chemical Co.
304 F. Supp. 2d 404 (E.D. New York, 2004)
In Re" Agent Orange" Product Liability Lit.
304 F. Supp. 2d 404 (E.D. New York, 2004)
Bourne Ex Rel. Bourne v. E.I. DuPont De Nemours & Co., Inc.
189 F. Supp. 2d 482 (S.D. West Virginia, 2002)
Plourde v. Gladstone
190 F. Supp. 2d 708 (D. Vermont, 2002)
Miller v. Diamond Shamrock Co.
275 F.3d 414 (Fifth Circuit, 2001)
Petitt v. Celebrity Cruises, Inc.
153 F. Supp. 2d 240 (S.D. New York, 2001)